Group 1 - The company announced the completion of business registration changes for its wholly-owned subsidiary, Yangling Buchang Pharmaceutical Co., Ltd. [1] - The changes include an updated business scope, which now encompasses traditional Chinese medicine extraction, medical research and development, and solar power technology services [1] - The registered capital of Yangling Buchang is 158 million RMB, and the company was established on August 31, 2010 [1] Group 2 - The company reported that its wholly-owned subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., has received approval from the Hebei Provincial Drug Administration for changes to its drug production license [3] - The changes include the addition of new production lines and workshops, specifically for soft capsule production and oral solution production lines [4][5] - The production license is valid until July 7, 2030, and the company is authorized to produce various forms of medications, including ointments, tablets, and oral solutions [4][5]

Core Viewpoint - Company Baichang Pharmaceutical's subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., has received a renewed drug production license from the Hebei Provincial Drug Administration, allowing for changes in production lines and facilities, which is expected to positively impact the company's future operations [1] Group 1: License and Production Changes - The renewed drug production license includes the addition of a new workshop and production line located at 16 Bichang Road, Qindu District, Xianyang City, Shaanxi Province [1] - The new workshop is designated for soft capsule production, and the production line is for oral solution dosage forms, specifically Vitamin D drops [1] - The company has commissioned Shaanxi Baichang Pharmaceutical Co., Ltd. to produce Vitamin D drops with specific dosages, which currently do not have approval numbers [1] Group 2: Operational Impact - The changes in the drug production license are expected to optimize the company's production structure and maintain stable production capacity to meet market demand [1] - The license changes are anticipated to have a positive impact on the company's future operations [1]

Core Viewpoint - Company has received approval from the Shandong Provincial Drug Administration to expand its production capabilities, which is expected to positively impact its future operations [1] Summary by Sections Production License Update - The company has been granted permission to add a new workshop and production line for the production of tablets, specifically in the Heze City location [1] - The new workshop added is the Comprehensive Preparation VI workshop, which will focus on tablet production [1] Contract Manufacturing Extensions - The company has extended its contract manufacturing agreements for various products: - Loratadine tablets and Montelukast chewable tablets until July 16, 2028 - Ibuprofen sustained-release capsules and Ezetimibe tablets until July 16, 2028 - Pregabalin capsules until March 31, 2028 - Donepezil hydrochloride tablets until July 7, 2030 [1] Impact on Operations - The changes in the production license, including the addition of workshops and production lines, are expected to optimize the company's production structure [1] - This will help maintain stable production capacity and meet market demand, leading to a positive impact on the company's future operations [1]

证券代码：603858证券简称：步长制药公告编号：2025-188 山东步长制药股份有限公司 关于控股子公司拟对外投资 设立子公司的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、对外投资概述 山东步长制药股份有限公司（以下简称"公司"）于2025年9月16日召开第五届董事会第三十二次会议， 审议通过了《关于上海合璞医疗科技有限公司拟对外投资的议案》，根据公司总体发展规划，为促进公 司控股子公司上海合璞医疗科技有限公司（以下简称"上海合璞"）的经营发展，上海合璞拟对外投资共 490万元，分别与济南恒德科技发展有限公司（以下简称"济南恒德科技"）、上海裹鼎科技有限公司 （以下简称"上海裹鼎科技"）共同投资设立两家新公司山东合璞锐诚医疗科技有限公司（以工商注册登 记为准）、湖北合璞医疗科技有限公司（以工商注册登记为准）。山东合璞锐诚医疗科技有限公司注册 资本400万元，其中上海合璞出资280万元，持股比例70%；济南恒德科技出资120万元，持股比例 30%。湖北合璞医疗科技有限公司注册资本300万元，其中上海合璞出资 ...

Group 1 - The company announced that its wholly-owned subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., received approval from the Hebei Provincial Drug Administration for changes in the production scope and entrusted production situation of its Drug Production License [1] - The production license includes various forms of medications such as ointments, tablets, solutions, and capsules, with the license valid until July 7, 2030 [1] - Changes in production lines include specific formulations such as "Oseltamivir Phosphate Oral Suspension" and "Donepezil Hydrochloride Tablets" [2][3] Group 2 - Baoding Tianhao Pharmaceutical Co., Ltd. has entrusted Shandong Buchang Pharmaceutical Co., Ltd. to produce Donepezil Hydrochloride Tablets, with the entrusted production valid until July 7, 2030 [3] - The changes in the Drug Production License are expected to optimize the production structure and maintain stable production capacity, positively impacting the company's future operations [4]

Core Viewpoint - The announcement highlights the approval of changes to the drug production license of Baoding Tianhao Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shandong Buchang Pharmaceutical Co., Ltd., which is expected to optimize production structure and maintain stable production capacity to meet market demand [1][4]. Summary by Sections Drug Production License Information - Baoding Tianhao Pharmaceutical Co., Ltd. has received permission from the Hebei Provincial Drug Administration to change the production scope and drug commissioning details of its drug production license [1]. - The production address is located at 128 Xinghua East Road, Dingxing County, Hebei Province, and the license is valid until July 7, 2030 [1]. Changes in Production Lines - The production line at Tianjin Hanrui Pharmaceutical Co., Ltd. has changed from "oral suspension" to "oral suspension (Oseltamivir phosphate dry suspension)" [2]. - The production line at Shandong Buchang Pharmaceutical Co., Ltd. has changed from "tablets" to "tablets (Donepezil hydrochloride tablets)" [2]. - The production line at Yangling Buchang Pharmaceutical Co., Ltd. has changed from "tablets" to "tablets (Sitagliptin and Metformin sustained-release tablets), tablets (Compound Sodium Sulfate tablets)" [2]. Commissioning Details - Baoding Tianhao Pharmaceutical Co., Ltd. has commissioned Shandong Buchang Pharmaceutical Co., Ltd. to produce Donepezil hydrochloride tablets, with the production address at 1566 Zhonghua West Road, Heze City, and the commissioning is valid until July 7, 2030 [3]. Impact on Future Operations - The changes in the drug production license are expected to positively impact the company's future operations by optimizing production structure and ensuring stable production capacity to meet market demand [4].

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of the company, Baoding Tianhao Pharmaceutical Co., Ltd., has received approval from the Hebei Provincial Drug Administration for changes in its production license, which will positively impact the company's future operations [1] Group 1 - The production license changes include modifications to the production scope for oral suspensions and tablets, as well as shared use of traditional Chinese medicine extraction and granules with Shandong Buchang Shenzhou Pharmaceutical Co., Ltd. [1] - The validity of the new production license is until July 7, 2030, which provides a long-term framework for the company's production capabilities [1] - These changes are expected to optimize the company's production structure and maintain stable production capacity to meet market demand [1]

Group 1 - Shandong Buchang Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., has received the "High-tech Enterprise Certificate" from relevant authorities, indicating its strong innovation and R&D capabilities [2] - The certificate is valid for three years, from November 11, 2024, and allows Baoding Tianhao to enjoy a reduced corporate income tax rate of 15% from 2024 to 2026 [2] - This recognition is expected to positively impact Baoding Tianhao's future development strategy and overall sustainable growth [2] Group 2 - The company has initiated a share repurchase program, approved by the board on December 26, 2024, with a maximum repurchase price set at 23 yuan per share [6] - As of April 30, 2025, the company has repurchased a total of 6,620,630 shares, representing 0.60% of its total share capital, with a total expenditure of approximately 98 million yuan [7] - The repurchase aligns with relevant regulations and the company's stated objectives, with ongoing compliance and disclosure obligations [7]

Core Viewpoint - The announcement details the changes in the business scope of the wholly-owned subsidiaries of Shandong Buchang Pharmaceutical Co., Ltd., specifically Baoding Tianhao Pharmaceutical Co., Ltd. and Shaanxi Buchang Pharmaceutical Co., Ltd., aimed at improving operational management [1][5]. Group 1: Business Scope Changes - Baoding Tianhao's previous business scope included the production of various pharmaceutical forms, while the new scope allows for broader technical services and drug production [1][2]. - Shaanxi Buchang's business scope has also been expanded to include additional services such as solar energy technology services and contract energy management, alongside its existing pharmaceutical production and wholesale activities [2]. Group 2: Financial Data - As of December 31, 2023, Baoding Tianhao reported total assets of 488.63 million, total liabilities of 319.97 million, and a net asset of 168.66 million, with an annual revenue of 1.21 billion and a net profit of 156.36 million [3]. - For the first nine months of 2024, Baoding Tianhao's total assets were 432.43 million, total liabilities were 288.80 million, net assets were 143.62 million, with a revenue of 906.63 million and a net profit of 131.32 million [3]. - Shaanxi Buchang reported total assets of 3.88 billion, total liabilities of 2.62 billion, and net assets of 1.26 billion as of December 31, 2023, with an annual revenue of 3.34 billion and a net profit of 548.81 million [4]. - As of September 30, 2024, Shaanxi Buchang's total assets were 3.87 billion, total liabilities were 2.98 billion, net assets were 882.65 million, with a revenue of 2.06 billion and a net profit of 254.70 million [4]. Group 3: Authorization and Management - The company has authorized its chairman and president to handle all procedures related to the changes in business scope, including signing relevant documents and submitting government approval applications [4].